Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone And/Or Its 9,11-Dehydroderivatives
US 12,337,002 In forceTerm ends Jul 24, 2028 · Medium confidence
20-year base term ends Jul 24, 2028
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 11,938,141), so the cap could be lower.
Jul 24, 2008
Jul 24, 2028
Jun 24, 2025
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 24, 2008, when the earliest non-provisional application in its chain was filed (this one was filed Nov 18, 2022) | Jul 24, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +136 days, USPTO patent term adjustment record | Dec 7, 2028 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,166,245, US 10,716,796, US 11,207,332, US 11,938,141, US 8,785,427, US 9,433,628) | capped to Jul 24, 2028 | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | No maintenance fee can end the term early | In force | High confidence |
| Computed term end | The steps above, in order | Jul 24, 2028 | Medium confidence |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.